Roivant Sciences
Venture capital · New York, New York, United States
Portfolio collected from the firm’s website, last checked Jun 28, 2026.Raises and exits come from each company’s own SEC and company records.
4Deep-tech portfolio1 active
3Portfolio exitsAcquired or listed
0Raises, 12 monthsLatest: Immunovant
7Co-investorsShare a portfolio company
Portfolio · 4 companies
| Company | Sector | Status | Latest raise | Raised |
|---|---|---|---|---|
| Aruvant Sciences | Biotech | Active | — | — |
| Immunovant | Biotech | Public | Jan 21, 2025 | $450.0M |
| Kiniksa Pharmaceuticals | Biotech | Public | Nov 23, 2020 | $5.9M |
| Proteovant Therapeutics | Biotech | Acquired | — | — |
Peer ranks
Portfolio size#108
Portfolio exits#69
Raises, 12 months#88
Co-investors#184
Co-investors
- Aisling CapitalVenture capital1 shared
- Deerfield Capital ManagementVenture capital1 shared
- Ikarian CapitalVenture capital1 shared
- Johnson & Johnson Development CorporationVenture capital1 shared
- Johnson & Johnson Robotics and Digital SolutionsVenture capital1 shared
- Sofinnova VenturesVenture capital1 shared
- Telegraph Hill PartnersVenture capital1 shared
Sectors
- Biotech4
Portfolios are collected from investors’ own websites and matched to tracked deep-tech companies by name; duplicate listings of the same firm are merged. Exits and raises come from each company’s own record: Form D through the latest filing.